middle.news
Can Vectus Biosystems Turn Around Losses with XORTX Deal on Horizon?
12:44pm on Thursday 26th of February, 2026 AEDT
•
Healthcare
Read Story
Can Vectus Biosystems Turn Around Losses with XORTX Deal on Horizon?
12:44pm on Thursday 26th of February, 2026 AEDT
Key Points
Half-year loss reduced to $731,694 from $1.1 million prior
Binding term sheet signed with XORTX for VB4-P5 renal fibrosis compound
Operating costs halved to $0.7 million amid commercialisation focus
Cash reserves stand at $330,000 with ongoing funding discussions
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
VECTUS BIOSYSTEMS (ASX:VBS)
OPEN ARTICLE